---
provider: claude
model: claude-opus-4-5
drug: Imatinib
disease: Chronic Myeloid Leukemia
query: 'Research the mechanism by which Imatinib affects Chronic Myeloid Leukemia.


  Produce a markdown response with EXACTLY this structure:


  ## Proposed mechanism summary

  2–3 paragraphs describing the mechanistic pathway from Imatinib to its effect

  on Chronic Myeloid Leukemia, with inline (PMID:XXXX) citations.


  ## Candidate PMIDs

  Bulleted list, 5–15 PMIDs ordered by relevance:

  - PMID:XXXXXXXX — One-sentence relevance note.

  - ...


  Only include PMIDs you verified exist via web search.


  ## Mechanism graph proposal (advisory)

  Drug → intermediate1 → intermediate2 → ... → Disease


  Each arrow labeled with a Biolink-style predicate (e.g., "decreases activity

  of", "positively regulates", "contributes to"). This topology is advisory —

  the curation agent will validate it.


  Output ONLY the markdown body. No preamble or closing remarks.

  '
generated_at: '2026-06-02T20:08:10+00:00'
ttl_days: 30
candidate_pmids:
- PMID:30700706
- PMID:11287972
- PMID:15618470
- PMID:10698507
- PMID:11423618
- PMID:11905636
- PMID:11423669
- PMID:14604282
- PMID:20537386
- PMID:24206122
- PMID:17900686
- PMID:20725992
- PMID:15840387
notes: input_tokens=199802, output_tokens=2025
---

## Proposed mechanism summary

Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder characterized by the Philadelphia chromosome, which results from a reciprocal translocation between chromosomes 9 and 22 [t(9;22)(q34;q11)] (PMID:30700706).

This translocation creates the chimeric BCR-ABL1 oncogene, which encodes a cytoplasmic protein tyrosine kinase with elevated and dysregulated enzymatic activity that plays a vital role in the pathogenesis and progression of CML.

The BCR-ABL oncoprotein triggers different downstream targets including c-Myc, STAT5 and CrkL, which participate in the control of cell differentiation, proliferation, migration and other cellular behaviors.

Imatinib (formerly STI571) is a selective tyrosine kinase inhibitor that specifically targets the BCR-ABL fusion protein (PMID:11287972, PMID:15618470).

Imatinib binds to the BCR-ABL kinase domain, which is in an inactive conformation in a pocket reserved for the ATP binding site, thus preventing the transfer of a phosphate group to tyrosine on the protein substrate and the subsequent activation of phosphorylated protein. As the result, the transmission of proliferative signals to the nucleus is blocked and leukemic cell apoptosis is induced.

Imatinib mesylate remarkably reduces tyrosine phosphorylation of Bcr-Abl, Cbl, and Crkl in a time-dependent manner, and inhibits activation of Stat5 rather than the MEK-ERK1/2 pathway.

BCR-ABL abnormally activates several downstream signaling pathways including RAS-MAPK, STAT5 and CRKL, which contribute to inhibition of apoptosis and induction of malignant transformation.

BCR-ABL-transformed leukaemic cells are addicted to Stat5 for maintaining the leukaemic state, and deletion of Stat5 in leukaemic cells results in G0/G1 cell cycle arrest followed by apoptosis.

In BCR-ABL-positive cells, the transcription factor STAT-5 is constitutively activated by tyrosine phosphorylation, and STAT-5 activation results in upregulation of bcl-XL and increased resistance to induction of apoptosis.

By inhibiting BCR-ABL kinase activity, imatinib suppresses STAT5-dependent expression of anti-apoptotic proteins such as Bcl-xL, thereby restoring the apoptotic response in leukemic cells (PMID:10698507).

## Candidate PMIDs

- PMID:11287972 — Landmark phase I clinical trial by Druker et al. demonstrating efficacy and safety of imatinib as a BCR-ABL tyrosine kinase inhibitor in CML patients.
- PMID:15618470 — Comprehensive review by Deininger, Buchdunger, and Druker on imatinib development as therapeutic agent for CML, covering preclinical and clinical development.
- PMID:11423618 — Gorre et al. study on clinical resistance to STI-571 caused by BCR-ABL gene mutation or amplification, demonstrating BCR-ABL as the central target.
- PMID:11905636 — Early review describing STI571 as an ABL-specific tyrosine kinase inhibitor that selectively kills BCR-ABL-containing cells.
- PMID:11423669 — Review article describing STI571 as a selective inhibitor for abl tyrosine kinases including bcr-abl.
- PMID:14604282 — Study showing imatinib reduces tyrosine phosphorylation of Bcr-Abl, Cbl, and Crkl and inhibits Stat5 activation.
- PMID:20537386 — Review on BCR-ABL tyrosine kinase inhibitors in CML treatment demonstrating clinical impact of BCR-ABL inhibition.
- PMID:24206122 — Overview of imatinib in CML describing ATP-binding site blockade and downstream pathway inhibition.
- PMID:17900686 — Study on phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant CML cells.
- PMID:20725992 — Paper demonstrating that BCR-ABL-transformed cells are addicted to Stat5 for maintaining the leukemic state.
- PMID:15840387 — Study demonstrating imatinib induces DNA damage in BCR-ABL-expressing leukemic cells but not normal lymphocytes.

## Mechanism graph proposal (advisory)

```
Imatinib
    ↓ [directly inhibits]
BCR-ABL tyrosine kinase
    ↓ [decreases activity of]
STAT5 (phosphorylated/active form)
    ↓ [decreases expression of]
BCL-XL (anti-apoptotic protein)
    ↓ [positively regulates]
Apoptosis of leukemic cells
    ↓ [treats]
Chronic Myeloid Leukemia
```

Alternative pathway representation:

```
Imatinib → [binds to ATP-binding site of] → BCR-ABL kinase → [inhibits phosphorylation of] → STAT5/CrkL/RAS-MAPK pathways → [decreases proliferation signals and anti-apoptotic signaling] → [induces apoptosis in] → Ph+ leukemic cells → [treats] → Chronic Myeloid Leukemia
```
